San Diego, California, May 25, 2016 /PRNewswire/ — Puregraft LLC is pleased to announce the publication of an independent clinical study utilizing Puregraft technology to naturally improve breast size and shape1. In this prospective study by lead author Professor Marcos Sforza (United Kingdom) and his co-workers, 26 patients underwent fat transfer to the breast, using Puregraft, to correct asymmetries and deformities following breast augmentation surgery.
The authors transferred an average of 280 cc of Puregraft processed fat per procedure and measured the percent of fat remaining 1-year after injection using 3-dimensional imaging software. Dr. Sforza and colleagues reported that an average of 72% of implanted fat remained 1-year post-operatively and patients reported a satisfaction rate of “excellent” in 83% of cases. The authors concluded that fat transplanted to the breast utilizing Puregraft technology was both predictable and reproducible.
According to Dr. Sforza, “Our work demonstrates that new technology can now make larger breasts using your own fat in a predictable and efficient way.” Added Dr. Sforza, “fat transfer in breast enlargement surgery is the future and how you treat the fat, in my mind, plays a role in achieving excellent results for patients.” Added Bradford Conlan, Chief Executive Officer of Puregraft, “We believe this data reinforces what we already know–Puregraft offers both patients and physicians a reliable method for fat transfer.”
The Puregraft family of products serve the needs of physicians performing fat transfer. Within 15 minutes, a physician can have access to a patient’s own purified, high quality fat tissue for aesthetic body contouring. Fat transfer remains one of the hottest growth segments in plastic and reconstructive surgery marketplace. Today, the Puregraft family of products have been used over 50,000 times in operating rooms around the world.
Learn more about Puregraft at www.thefatexperts.com
 A Preliminary Assessment of the Predictability of Fat Grafting to Correct Silicone Breast Implant-Related Complications, Marcos Sforza MD, Katarina Andjelkov MD, PhD, Renato Zaccheddu MD, Rodwan Husein, Connor Atkinson. Aesthetic Surgery Journal published online 7 May 2016
Puregraft LLC is a private company owned by Bimini Technologies. The Bimini portfolio of products also includes Kerastem Technologies LLC (www.kerastem.com) a leading hair growth company currently engaged in a Phase II clinical trial in the United States. The Kerastem Hair Therapy is CE Mark approved outside the United States.